Pylarify (piflufolastat f-18) from progenics pharmaceuticals INC.:1106332 [26-000012]
Ended Awarded Last action
- Contract number
- 75N90026F00006
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
NIH Clinical Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $529,273
Award facts
- Opportunity
-
- Piflufolastat F-18 injection drugs (Pylarify) (Notice of Intent to sole source) Pre-Solicitation · NOICC26000012 · Posted Sep 25, 2025
- Contract value 100% obligated
- $529,273.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $180,436 | |
| Exercise an Option | $185,645 | |
| Original award | $163,192 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a $529,273.12 firm fixed-price delivery order from the NIH Clinical Center on October 1, 2025, for PYLARIFY (piflufolastat F-18), a specialized radiopharmaceutical diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. The order, with an ultimate completion date of September 30, 2026, carries no set-aside designation and will be performed at the contractor's manufacturing and distribution facility in North Billerica, Massachusetts. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract framework that establishes the pricing and terms for federal procurement of the company's radiopharmaceutical products.
The NIH Clinical Center's award is part of a broader federal procurement pattern for PYLARIFY products, which Progenics has supplied to the federal healthcare system through over 150 individual contract awards. The company maintains substantial indefinite delivery vehicles with multiple federal agencies, including a major $290 million Federal Supply Schedule contract with Veterans Integrated Service Network 12 (effective through March 31, 2030) and multiple blanket purchase agreements with the Department of Veterans Affairs and Defense Health Agency. These master contract structures enable federal medical facilities nationwide to efficiently procure critical radiopharmaceutical supplies for oncology diagnostic imaging programs supporting military personnel, veterans, and federal healthcare beneficiaries.
Quick answers
Who was awarded contract 75N90026F00006?
75N90026F00006 was awarded to Progenics Pharmaceuticals Inc. by NIH Clinical Center (National Institutes of Health) on October 1, 2025.
How much is contract 75N90026F00006 worth?
The government has obligated $529,273 on 75N90026F00006.
Is contract 75N90026F00006 an order under another contract?
Yes. 75N90026F00006 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 75N90026F00006 competed?
The extent of competition for 75N90026F00006 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award